PolyPid Ltd. (PYPD) - What Are Researchers Thinking About This Stock?

Key Points

• Analyst sentiment is moderately bullish: Five brokerages give PolyPid an average “Moderate Buy” rating, with four buys and one sell. The average 12-month price target is $11.00, compared with the stock’s reported price of $5.29.
• Institutional ownership has increased: Several investment firms recently initiated or expanded positions, and institutions and hedge funds collectively own 26.47% of PolyPid’s outstanding shares.
• PolyPid remains an early-stage, loss-making biotech: The company’s lead candidate is D-PLEX100, a sustained-release doxycycline treatment, while its latest quarterly loss of $0.35 per share exceeded analysts’ expected loss of $0.38.

Shares of PolyPid Ltd. (NASDAQ:PYPD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $11.00.

A number of brokerages have recently weighed in on PYPD. Craig Hallum set a $12.00 price target on PolyPid in a report on Wednesday, July 22nd. Weiss Ratings reissued a "sell (d-)" rating on shares of PolyPid in a research note on Friday, September 18th. HC Wainwright restated a "buy" rating and set a $13.00 price objective on shares of PolyPid in a research report on Tuesday, July 21st. Finally, Oppenheimer initiated coverage on PolyPid in a research report on Tuesday. They set an "outperform" rating and a $10.00 price objective for the company.

Institutional Trading of PolyPid

Institutional investors have recently made changes to their positions in the stock. B. Riley Wealth Advisors Inc. increased its position in PolyPid by 32.7% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 20,085 shares of the company's stock worth $106,000 after purchasing an additional 4,955 shares during the last quarter. HighTower Advisors LLC acquired a new stake in shares of PolyPid during the 2nd quarter valued at about $56,000. AXQ Capital LP acquired a new stake in shares of PolyPid during the 2nd quarter valued at about $87,000. Renaissance Technologies LLC bought a new stake in shares of PolyPid in the 1st quarter valued at approximately $81,000. Finally, Connective Capital Management LLC bought a new stake in shares of PolyPid in the 2nd quarter valued at approximately $343,000. 26.47% of the stock is currently owned by institutional investors and hedge funds.

PolyPid Stock Performance

PolyPid stock opened at $5.29 on Tuesday. PolyPid has a 52 week low of $3.40 and a 52 week high of $5.73. The firm has a market capitalization of $100.93 million, a price-to-earnings ratio of -3.57 and a beta of 1.38. The company has a 50 day moving average price of $5.13 and a 200 day moving average price of $4.71.

PolyPid (NASDAQ:PYPD - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.03. Equities analysts forecast that PolyPid will post -0.92 earnings per share for the current fiscal year.

About PolyPid

PolyPid Ltd. NASDAQ: PYPD is a clinical-stage biopharmaceutical company focused on developing locally administered therapies designed to provide controlled and sustained drug release at treatment sites. The company's technology is intended to maintain therapeutic drug concentrations over extended periods while limiting systemic exposure.

PolyPid's lead product candidate is D-PLEX100, an investigational formulation based on doxycycline and the company's proprietary PLEX polymeric matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.